Consequently, when administering a drug inhibitor of the PD-1/L1 axis, such as pembrolizumab or nivolumab, the cells are more vulnerable to the action of T cells, but the latter are not present in the tumor microenvironment, therefore they cannot kill them. Here, PDCD1 is linked to neoplasm.